Glaxo Gets OFT Complaint for Paying to Delay Seroxat Copies

GlaxoSmithKline Plc was sent an antitrust complaint by U.K. regulators who say the company may have colluded with generic-drug makers to keep copies of its Seroxat antidepressant off the market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.